Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study.

Abstract

The authors assessed the safety and efficacy of creatine monohydrate (Cr) in various types of muscular dystrophies in a double-blind, crossover trial. Thirty-six patients (12 patients with facioscapulohumeral dystrophy, 10 patients with Becker dystrophy, 8 patients with Duchenne dystrophy, and 6 patients with sarcoglycan-deficient limb girdle muscular dystrophy) were randomized to receive Cr or placebo for 8 weeks. There was mild but significant improvement in muscle strength and daily-life activities by Medical Research Council scales and the Neuromuscular Symptom Score. Cr was well tolerated throughout the study period.

• Authors: M C Walter, H Lochmüller, P Reilich, T Klopstock, R Huber, M Hartard, M Hennig, D Pongratz, W Müller-Felber
• Journal: Neurology (Neurology) Vol. 54 Issue 9 Pg. 1848-50 (May 09 2000) ISSN: 0028-3878 [Print] United States
• PMID: 10802796 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Creatine

Topics

• Activities of Daily Living (classification)
• Adolescent
• Adult
• Child
• Child, Preschool
• Creatine (administration & dosage, adverse effects)
• Double-Blind Method
• Female
• Humans
• Isometric Contraction (drug effects)
• Male
• Middle Aged
• Muscular Dystrophies (drug therapy, genetics)
• Neurologic Examination (drug effects)
• Treatment Outcome
• Vital Capacity (drug effects)